Leukemia Research
Volume 28, Issue 8 , Pages 791-803 , August 2004

Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression

  • Azra Raza

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-563-4500; fax: +1-312-563-4170.
    • ,
  • Silvia Buonamici

      Affiliations

    • Department of Pathology, University of Illinois, Chicago, IL, USA
    • ,
  • Laurie Lisak

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Sarah Tahir

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Donglan Li

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Mehnaz Imran

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Nusrat Ijaz Chaudary

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Hassan Pervaiz

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • J.Alejandro Gallegos

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • M.Imran Alvi

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Muhammad Mumtaz

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Sefer Gezer

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Parameswaran Venugopal

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Poluru Reddy

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Naomi Galili

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Anna Candoni

      Affiliations

    • Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA
    • ,
  • Jack Singer

      Affiliations

    • Cell Therapeutics Inc., Seattle, Washington, USA
    • ,
  • Giuseppina Nucifora

      Affiliations

    • Department of Pathology, University of Illinois, Chicago, IL, USA

References 

  1. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27(February(2)):95–120
  2. Paquette RL. Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Huntingt). 2002;16(September(9 Suppl 10)):153–161
  3. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83(April(4)):358–368
  4. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 2000;24(August(8)):653–663
  5. Kasper C, Zahner J, Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol. 2002;128(September(9)):497–502
  6. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86(1):268–276
  7. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97(March(5)):1427–1434
  8. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al.  Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98(4):958–965
  9. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62(July(14)):3893–3903
  10. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54(September(6)):831–840
  11. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA. 1996;93(February(4)):1642–1647
  12. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia. 1999;13(March(3)):348–357
  13. Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem. 2001;276(November(48)):44936–44943
  14. Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA. 2000;97(February(4)):1760–1765
  15. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11(December(12)):2022–2031
  16. Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia. 1997;11(March(3)):352–358
  17. Pintado T, Ferro MT, San Roman C, Mayayo M, Larana JG. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer. 1985;55(February(3)):535–541
  18. Jenkins RB, Tefferi A, Solberg LA, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet. 1989;39(June(2)):167–179
  19. Jotterand Bellomo M, Parlier V, Muhlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet. 1992;59(April(2)):138–160
  20. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, et al.  Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia. 1994;8(August(8)):1318–1326
  21. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995;91(October(2)):490–501
  22. Horsman DE, Gascoyne RD, Barnett MJ. Acute leukemia with structural rearrangements of chromosome 3. Leuk Lymph. 1995;16(February(5–6)):369–377
  23. Breccia M, Petti MC, Ottaviani E, Mancini M, D’Elia GM, Mecarocci S, et al.  Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI1 gene role?. Br J Haematol. 2002;118(August(2)):438–441
  24. Sancho JM, Ribera JM, Granada I, Navarro JT, Milla F, Feliu E. Myelofibrosis in myeloid malignancies with 3q26 cytogenetic abnormalities. Haematologica. 2000;85(May(5)):554–555
  25. van Doorn-Khosrovani SB, Erpelinck C, van Putten WLJ, Valk PJM. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101:837–845
  26. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al.  World Health Organization(WHO) International Working Group   Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(December(12)):3671–3674
  27. Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia. 1999;13:1639–1645
  28. Senyuk V, Chakraborty S, Mikhail F, Zhao R, Chi Y, Nucifora G. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene. 2002;21:3232–3240
  29. List AF. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin Oncol. 1999;26(April(2 Suppl 7)):61–65
  30. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group. J. Clin. Oncol. 2002;20(May(10)):2429–2440
  31. Beran M, Kantarjian HM. Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies. Ann NY Acad Sci. 2000;922:247–259
  32. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(August(7)):481–487
  33. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, et al.  Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1(August(10)):851–860
  34. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2(September(9)):705–713
  35. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, et al.  Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol. 2002;39(April(2 Suppl 1)):22–26
  36. Davison K, Mann KK, Miller WH. Arsenic trioxide: mechanisms of action. Semin. Hematol. 2002;39(April(2 Suppl 1)):3–7
  37. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, et al.  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an anti-leukemic effect via inhibition of angiogenesis. Blood. 2000;96:1525–1530
  38. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 2001;20(October(49)):7257–7265
  39. Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of EVI1 gene in myelodysplastic syndromes. Leukemia. 1995;9:203–205
  40. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, et al.  Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood. 1994;84(August(4)):1243–1248
  41. Xi ZF, Russell M, Woodward S, Thompson F, Wagner L, Taetle R. Expression of Zn finger gene, EVI1, in acute promyelocytic leukemia. Leukemia. 1997;11(February(2)):212–220

PII: S0145-2126(03)00417-X

doi: 10.1016/j.leukres.2003.11.018

Leukemia Research
Volume 28, Issue 8 , Pages 791-803 , August 2004

Article Tools

* Image Usage & Resolution